A phase III trial evaluating glofitamab in combination with gemcitabine plus oxaliplatin versus rituximab in combination with gemcitabine and oxaliplatin in patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL).

被引：11
|
作者：
Hertzberg, Mark
Ku, Matthew
Catalani, Olivier
Althaus, Betsy
Simko, Stephen
Gregory, Gareth P.
机构：
[1] Prince Wales Hosp, Sydney, NSW, Australia
[2] St Vincents Hosp, Melbourne, Vic, Australia
[3] Univ Melbourne, Melbourne, Vic, Australia
[4] F Hoffmann La Roche Ltd, Basel, Switzerland
[5] Genentech Inc, San Francisco, CA 94080 USA
[6] Monash Univ, Sch Clin Sci Monash Hlth, Melbourne, Vic, Australia
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2021年 / 39卷 / 15期
关键词：
D O I：
10.1200/JCO.2021.39.15_suppl.TPS7575
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
TPS7575
引用
收藏
页数：3
相关论文
共 50 条
  • [21] Rituximab plus gemcitabine and oxaliplatin in patients with refractory/relapsed diffuse large B-cell lymphoma who are not candidates for high-dose therapy. A phase II Lymphoma Study Association trial
    Mounier, Nicolas
    El Gnaoui, Taoufik
    Tilly, Herve
    Canioni, Daniele
    Sebban, Catherine
    Casasnovas, Rene-Olivier
    Delarue, Richard
    Sonet, Anne
    Beaussart, Pauline
    Petrella, Tony
    Castaigne, Sylvie
    Bologna, Serge
    Salles, Gilles
    Rahmouni, Alain
    Gaulard, Philippe
    Haioun, Corinne
    HAEMATOLOGICA, 2013, 98 (11) : 1726 - 1731
  • [22] Rituximab plus gemcitabine and oxaliplatin (R-GemOx) in refractory/relapsed diffuse large B-cell lymphoma: a real-life study in patients ineligible for autologous stem-cell transplantation
    Cazelles, Clarisse
    Belhadj, Karim
    Vellemans, Helene
    Camus, Vincent
    Poullot, Elsa
    Gaulard, Philippe
    Veresezan, Liana
    Itti, Emmanuel
    Becker, Stephanie
    Carvalho, Muriel
    Dupuis, Jehan
    Le Bras, Fabien
    Lemonnier, Francois
    Roulin, Louise
    El Gnaoui, Taoufik
    Jardin, Fabrice
    Mounier, Nicolas
    Tilly, Herve
    Haioun, Corinne
    LEUKEMIA & LYMPHOMA, 2021, 62 (09) : 2161 - 2168
  • [23] POLARGO: A Randomized Phase III Study Evaluating Polatuzumab Vedotin Plus Rituximab, Gemcitabine, and Oxaliplatin in Patients with Relapsed/ Refractory Diffuse Large B-Cell Lymphoma Who Had Received One or More Previous Therapies
    McMillan, Andrew K.
    Matasar, Matthew J.
    Sancho, Juan-Manuel
    Viardot, Andreas
    Hernandez, Juana
    Perretti, Thomas
    Haioun, Corinne
    BLOOD, 2019, 134
  • [24] Rituximab Plus Gemcitabine and Oxaliplatin As Salvage Therapy in Patients with Relapsed/Refractory Mantle-Cell Lymphoma
    Gironella, Mercedes
    Lopez, Andres
    Merchan, Brayan
    Abrisqueta, Pau
    Jaramillo, Anny
    Bosch, Francesc
    BLOOD, 2012, 120 (21)
  • [25] Rituximab Plus Gemcitabine and Oxaliplatin as Salvage Therapy In Patients with Relapsed/Refractory Mantle-Cell Lymphoma
    Gironella, Mercedes
    Lopez, Andres
    Pau, Abrisqueta
    Anny, Jaramillo
    Noelia, Purroy
    Bosch, Francesc
    BLOOD, 2010, 116 (21) : 1165 - 1165
  • [26] Dual epigenetic agents plus rituximab-gemcitabine-oxaliplatin as salvage treatment in relapsed/refractory diffuse large B-cell lymphoma patients failure of salvage chemotherapy
    Qu, Changju
    Ping, Nana
    Kong, Danqing
    Liu, Aining
    Liu, Hailing
    Xu, Ting
    Xia, Fan
    Wu, Depei
    Jin, Zhengming
    HEMATOLOGICAL ONCOLOGY, 2022, 40 (05) : 914 - 921
  • [27] Rituximab Plus Gemcitabine and Oxaliplatin (R-GemOx) in Refractory/Relapsed (R/R) DLBCL. a Real Life Study in Patients Ineligible for Autologous Transplantation
    Cazelles, Clarisse
    Belhadj, Karim
    Vellemans, Helene
    Camus, Vincent
    Copie, Christiane
    Veresezan, Liana
    Itti, Emmanuel
    Becker, Stephanie
    Carvalho, Muriel Verlinde
    Dupuis, Jehan
    Le Bras, Fabien
    Lemonnier, Francois
    Roulin, Louise
    El Gnaoui, Taoufik
    Jardin, Fabrice
    Mounier, Nicolas
    Tilly, Herve
    Haioun, Corinne
    BLOOD, 2019, 134
  • [28] Rituximab, gemcitabine, cisplatin, and methylprednisolone (R-GEM-P) in treatment of relapsed diffuse large B-cell lymphoma (DLBCL).
    Barton, Sarah Rachel
    Hawkes, Eliza Anne
    Cunningham, David
    Peckitt, Clare
    Chua, Sue
    Wotherspoon, Andrew
    Attygalle, Ayoma
    Horwich, Alan
    Dearden, Claire E.
    Potter, Mike
    Chau, Ian
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [29] Rituximab, gemcitabine and oxaliplatin (R-GEMOX): A promising regimen for refractory/relapsed B-cell lymphoma, a single institution pilot study
    El Gnaoui, T
    Dupuis, J
    Joly, B
    Belhadj, K
    Rahmouni, A
    Copie-Bergman, C
    Allain, A
    Tabah-Fisch, I
    Reyes, F
    Haioun, C
    ANNALS OF ONCOLOGY, 2005, 16 : 182 - 182
  • [30] Phase 1/2 trial of acalabrutinib plus pembrolizumab (Pem) in relapsed/refractory (r/r) diffuse large B-cell lymphoma (DLBCL).
    Witzig, Thomas E.
    Maddocks, Kami J.
    De Vos, Sven
    Lyons, Roger M.
    Edenfield, William Jeffery
    Sharman, Jeff Porter
    Vose, Julie
    Yimer, Habte Aragaw
    Wei, Helen
    Chan, Edward M.
    Patel, Priti
    Di Simone, Christopher
    Gandhi, Mitul
    Vaughn, Jennifer
    Kolibaba, Kathryn
    Cheson, Bruce D.
    Samaniego, Felipe
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
12345